** Shares of drug developer Fractyl Health GUTS.O rise 6.7% to $1.27 premarket
** Co says early-stage data shows its weight management device Revita helps maintain weight in patients after they discontinued taking weight-loss drugs
** One month post-procedure, seven patients experienced an average weight regain of just 1.2%, compared with the ~3% typically observed at this time period after GLP-1 discontinuation based on prior clinical studies - GUTS
** Co expects to announce additional data from the study during Q3 of this year
** Shares of the company have fallen 42.2% YTD
(Reporting by Sneha S K )
(( Sneha.SK@thomsonreuters.com ))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。